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Abstract
Introduction: In addition to its direct proinflammatory activity, extracellular high mobility group box protein
1 (HMGB1) can strongly enhance the cytokine response evoked by other proinflammatory molecules, such as
lipopolysaccharide (LPS), CpG-DNA and IL-1b, through the formation of complexes. Extracellular HMGB1 is
abundant in arthritic joint tissue where it is suggested to promote inflammation as intra-articular injections of
HMGB1 induce synovitis in mice and HMGB1 neutralizing therapy suppresses development of experimental arthritis.
The aim of this study was to determine whether HMGB1 in complex with LPS, interleukin (IL)-1a or IL-1b has
enhancing effects on the production of proinflammatory mediators by rheumatoid arthritis synovial fibroblasts
(RASF) and osteoarthritis synovial fibroblasts (OASF). Furthermore, we examined the toll-like receptor (TLR) 4 and
IL-1RI requirement for the cytokine-enhancing effects of the investigated HMGB1-ligand complexes.
Methods: Synovial fibroblasts obtained from rheumatoid arthritis (RA) and osteoarthritis (OA) patients were
stimulated with HMGB1 alone or in complex with LPS, IL-1a or IL-1b. Tumour necrosis factor (TNF) production was
determined by enzyme-linked immunospot assay (ELISPOT) assessment. Levels of IL-10, IL-1-b, IL-6 and IL-8 were
measured using Cytokine Bead Array and matrix metalloproteinase (MMP) 3 production was determined by ELISA.
Results: Stimulation with HMGB1 in complex with LPS, IL-1a or IL-1b enhanced production of TNF, IL-6 and IL-8.
HMGB1 in complex with IL-1b increased MMP production from both RASF and OASF. The cytokine production was
inhibited by specific receptor blockade using detoxified LPS or IL-1 receptor antagonist, indicating that the
synergistic effects were mediated through the partner ligand-reciprocal receptors TLR4 and IL-1RI, respectively.
Conclusions: HMGB1 in complex with LPS, IL-1a or IL-1b boosted proinflammatory cytokine- and MMP production
in synovial fibroblasts from RA and OA patients. A mechanism for the pathogenic role of HMGB1 in arthritis could
thus be through enhancement of inflammatory and destructive mechanisms induced by other proinflammatory
mediators present in the arthritic joint.
Introduction
The highly conserved protein high mobility group box
protein 1 (HMGB1) exerts vital functions in the nucleus
of all eukaryotic cells. When tissue injury is inflicted and
inflammation is induced, HMGB1 can be released extra-
cellularly and can then convey inflammatory functions.
Extracellular HMGB1 may induce cytokine production,
up-regulation of adhesion molecules on endothelial cells
and activation of dendritic cells and T cells [1-11]. The
reported presence of extracellular HMGB1 in multiple
inflammatory conditions and the beneficial effects of
HMGB1 blockade in preclinical models of inflammatory
diseases have thus led to the acknowledgement of
HMGB1 as an inflammatory mediator with pathogenic
functions in several inflammatory diseases (reviewed
in [12]).
HMGB1 interacts with the receptor for advanced gly-
cated end products (RAGE), Toll-like receptor (TLR) 2
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tors are known to be involved in inflammatory processes
and to possess the ability to activate NFB translocation.
RAGE-HMGB1 interaction has mainly been studied
regarding induction of cell migration while HMGB1
interaction with TLR2 and TLR4 mediates immune acti-
vation. We recently reported that HMGB1-induced
cytokine production in macrophages is mediated via
TLR4 and requires a reduced cysteine with a thiol group
in amino acid position 106, supplementing the findings
of Kazama et al. that HMGB1 released from apoptotic
cells contains an oxidized cysteine in position 106 that
induces tolerance rather than immune activation [13,14].
A second mechanism for the proinflammatory func-
tion of HMGB1 is due to the ability of HMGB1 to form
complexes with inflammation-inducing agents such as
LPS, IL-1b, CpG-DNA (short single-stranded synthetic
DNA molecules that contain a cytosine followed by a
guanine) and the TLR2-ligand Pam3CSK4.S u c hc o m -
plexes have been demonstrated to strongly enhance
cytokine production in cell cultures. Additionally, in an
experimental model of systemic lupus erythematosus
HMGB1 was detected in circulating nucleosome com-
plexes and the necessity of HMGB1 for these complexes
to be immunogenic and to induce production of anti-
DNA antibodies were demonstrated [15-20]. The mole-
cular mechanism underlying the inflammatory activity
of HMGB1 complexes and their ability to induce an
enhanced response as compared to the partner molecule
alone has not previously been addressed. Interestingly, it
appears to be independent of the HMGB1 redox status
as HMGB1, unable to induce cytokine production per
se, still has the ability to induce such enhancement.
We and others have demonstrated an extracellular
expression of HMGB1 in synovial tissue biopsies from
rheumatoid arthritis (RA) patients and in joints from
mice and rats with adjuvant-induced arthritis or collagen
type II-induced arthritis [21-24]. Additionally, extranuc-
lear HMGB1 localisation has been described in synovial
tissue from osteoarthritis (OA) patients and in bovine
osteoarthritic cartilage specimens [25,26]. Evidence for
an active role of HMGB1 in arthritis pathogenesis is pro-
vided by studies demonstrating that a single injection of
recombinant HMGB1 into knee joints of mice induces
chronic synovitis [27] and, conversely, neutralisation of
HMGB1 by treatment with antibodies or with a specific
HMGB1 peptide antagonist significantly suppresses
arthritis development in several studies [24,28-31].
Synovial fibroblasts (SFs) have been demonstrated to
play a central role in arthritis pathogenesis, promoting
both inflammation and bone and cartilage destruction
[32,33]. SFs display an activated phenotype with up-
regulated expression of multiple TLRs and interleukin 1
receptor type I (IL-1RI) [34-37].
We investigated whether the arthritogenic properties of
HMGB1 could involve stimulation of SFs by HMGB1
complexes. We chose to study complexes formed by
HMGB1 and endogenous mediators already described to
be present in arthritic joints, that is, IL-1a and IL-1b, and
with LPS which may also appear in arthritic joints
[23,38-42]. We could demonstrate that SFs obtained from
RA or OA patients responded to HMGB1 in complex with
IL-1a, IL-1b or LPS, respectively, with enhanced produc-
tion of tumor necrosis factor (TNF), IL-1, IL-6, IL-8 and
MMP-3 and that the enhancement was mediated by inter-
action with IL-1RI or with TLR4, respectively. Knowing
that uncomplexed HMGB1, depending on its redox status
may or may not stimulate cytokine production, we initially
tested the suitability of various HMGB1 batches for the
present studies. We observed that every tested HMGB1
preparation, regardless of its inherent function to stimulate
cytokine production, was capable to act in synergy in com-
plexes with either LPS or IL-1a or b. In order to facilitate
the read-out of the HMGB1-complex experiments we
thus chose to base our studies on HMGB1 batches that
did not induce cytokine formation per se.T h e s ee x p e r i -
ments have enabled us to propose a mechanism by which
HMGB1 contributes to both inflammatory and destructive
processes activated during arthritis.
Materials and methods
Cell cultures
Synovial fibroblasts obtained from nine RA and six OA
patients were purchased from Asterand, (Detroit, MI,
USA) or propagated from synovial tissues from RA and
OA patients undergoing joint replacement surgery [43].
Briefly, synovial tissues were minced and explants were
maintained in DMEM supplemented with 10% heat inacti-
vated FCS (PAA Laboratories, Linz, Austria), 100 U/ml
penicillin, 100 μg/ml streptomycin and HEPES (Life Tech-
nologies, Paisely, Scotland, UK) (complete DMEM) in a
tissue culture incubator at 37°C with 5% CO2 content.
After one to two weeks of culture the tissue specimens
and non-adherent cells were discarded and cells were tryp-
sinized with Trypsin-EDTA (Gibco, Scotland, UK) and
subcultured by trypsination three to four weeks after initial
explantation (at 80% confluence). All SF were used for
experiments between passages 3 to 8. This study was
approved by the Institutional Ethical Committee (Solna,
Stockholm, Sweden; ethical number 2009/1262-31/3) and
is in compliance with all ethical standards and patients’
consent according to the Declaration of Helsinki.
Preparation of rHMGB1 from E. coli
Recombinant rat HMGB1 (rHMGB1) with a 99% iden-
tity to human HMGB1 [44] and containing a calmodu-
lin-binding protein tag was expressed in E. coli strain
BL21 (for sequence see ref [45]). Protein was purified by
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GL column, GE Healthcare, Chalfont St. Giles, UK) and
calmodulin affinity chromatography (Calmodulin
sepharose 4B, GE Healthcare). Endotoxin was removed
by filtration through Acodisc Units with Mustang E
Membranes (0.25 μm, Pall Life Sciences, East Hills, NY,
USA), yielding endotoxin levels below 0.03 EU/μgp r o -
tein as measured by the Limulus assay. Preparations of
H M G B 1i n2 0m M3 - ( N - M o r p h o l i n o )p r o p a n e s u l f o n i c
acid (MOPS), 400 mM NaCl, 20 mM EGTA, 10 mM
dithiothreitol at pH 8.0 were stored at -80°C until the
day of use. The HMGB1 used in the studies could not
induce cytokine production per se.
Immunocytochemistry; TLR4 and IL-1RI expression in
synovial fibroblasts
Cells were cultured on 8-well culture slides, formalde-
hyde-fixed and subsequently stained for the presence of
TLR4 and IL-1RI as previously described [30]. Briefly,
slides were incubated with 2% fetal calf sera for 10 min-
utes and thereafter incubated overnight with anti-TLR4
antibody (sc-8694 Santa Cruz Biotechnology Inc, Santa
Cruz, CA, USA) or monoclonal rabbit anti-IL-1RI
(Epitomics, Burlingame, CA, USA). Subsequently, cells
were incubated with Alexa Fluor
© 594-conjugated anti-
goat or rabbit antibodies (Molecular Probes, Invitrogen,
Eugene, OR, USA) and counterstained with Hoechst
33342. PBS supplemented with 0.1% saponin was used in
all steps of the staining procedure. In order to verify the
staining specificity, parallel blocking experiments invol-
ving preabsorption of the specific primary antibody with
blocking peptide or using a primary isotype-matched
irrelevant IgG were performed.
Preparation of HMGB1-LPS, HMGB1-IL-1a and HMGB1-IL-
1b complexes
HMGB1 diluted in PBS was incubated with IL-1a,I L - 1 b
(R&D Systems, Minneapolis, MN, USA) or LPS (L-6529
Sigma, Saint Louis, MO, USA), respectively, in different
ratios to give the indicated final concentrations in cell cul-
tures. Solutions were incubated at 4°C for 16 h before
addition to cell cultures. Formation of complexes has been
previously demonstrated [17,18].
TNF Elispot assay
TNF Elispot assay (Enzyme-linked immunospot assay,
R & DS y s t e m s ,M i n n e a p o l i s ,M N ,U S A )w a sp e r f o r m e d
according to the manufacturer’s instructions. Briefly,
Multiscreen 96-well HTS Plate Clear (MSIPS4510, Milli-
pore, Stockholm, Sweden) were pre-wetted with 35%
ethanol, washed and coated with capture antibody
(Gibco, Scotland, UK) overnight. After washing, plates
were blocked with cell-specific medium for 2 h in a tissue
culture incubator.
Synovial fibroblasts grown to confluence were trypsi-
nized with Trypsin-EDTA and washed with complete
DMEM. Cell viability was assessed using Trypan blue
(Merck, Darmstadt, Germany) exclusion in every experi-
mental set up and determined to be 95 to 100%.
Cells were plated at 4,000 cells/well and allowed to rest
for 15 to 17 h in a tissue culture incubator at 37°C with 5%
CO2 content. Medium was discarded and cells were washed
twice with OPTIMEM (Gibco, Scotland, UK) supplemented
with 100 U/ml penicillin, 100 μg/ml streptomycin and sti-
mulated for 9 h in OPTIMEM with 4 μg/ml or 100 ng/ml
rHMGB1 alone or together (in complex or separately) with
1 to 100 ng/ml LPS or 0.05 to 0.5 ng/ml rIL-1b as indicated.
In some experiments, cells were pre-treated for 1 to 2 h
with 0.5 to 5 μg/ml IL-1RA, anakinra (Kineret; Amgen
Europe, Breda, The Netherlands) or 10 μg/ml detoxified
LPS L-9023 (Sigma, Saint Louis, MO, USA). Following this
stimulation plates were placed on ice for 15 minutes,
washed with PBS/0.05% Tween 20 (PBS/Tw) and biotiny-
lated TNF detection antibody was added. After overnight
incubation plates were washed and incubated with Strepta-
vidine-HRP (Mabtech AB, Stockholm, Sweden).
Spots were visualized following addition of tetramethyl-
benzidine (TMB) chromogen liquid substrate (Mabtech)
and analyzed using an AID EliSpot Reader System, (AID,
Strassberg, Germany).
Cytometric bead array (CBA) for detection of cytokine
production
Cells were harvested as described for the TNF Elispot assay
and 1 ml of 8 × 10
4 cells/ml in complete DMEM were pla-
ted in 12-well plates and rested for 15 to 17 h. Medium was
discarded and cells were washed with OPTIMEM supple-
mented with 100 U/ml penicillin and 100 μg/ml streptomy-
cin and stimulated as indicated with 4 μg/ml or 100 ng/ml
rHMGB1 alone or in complex with 1 to 100 ng/ml LPS or
0.05 to 0.5 ng/ml, rIL-1a or rIL-1b, respectively. In some
experiments cells were pre-treated for 1 to 2 h with 0.5 to
5 μg/ml IL-1RA anakinra or 10 μg/ml detoxified LPS L-
9023. Supernatants were collected after 24 h of stimulation
and stored at -20°C until analysis. Cell viability was assessed
using Trypan blue (Merck, Darmstadt, Germany) exclusion
in every experimental set up, at the beginning and at the
end of every experiment and determined to be 95 to 100%.
Proinflammatory cytokine production was determined
using flow CBA (B&D Biosciences, Pharmingen, San
Diego, CA, USA) and analyzed according to the manu-
facturer’s instructions.
ELISA assay for detection of MMP-3
Cells were cultured and stimulated as described above and
supernatants collected after 24 h. The release of MMP-3
was analysed by ELISA (R&D Systems, Minneapolis, MN,
USA) according to the manufacturer’si n s t r u c t i o n .
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Kruskal-Wallis non-parametric ANOVA, Wilcoxon paired
test or Mann Whitney were used to test statistical signifi-
cance. All pair-wise comparisons were adjusted using
Dunn’s Multiple Comparisons Test. A P-value below 0.05
was considered to be statistically significant. The computer
software program GraphPad Prism version 5 for Windows
(GraphPad Software, San Diego, CA, USA) was used for
all statistical tests.
Results
TLR4 and IL-1RI are expressed by synovial fibroblasts
TLR4 and IL-1RI, the reciprocal signalling receptors for
the HMGB1 complex partner molecules LPS, IL-1a and
IL-1b, were expressed on synovial fibroblasts from both
RA (RASFs) and OA (OASFs) patients as demonstrated by
immunofluoresencent staining. A strong expression of
both TLR4 and IL-1RI was recorded (Figure 1).
HMGB1 in complex with LPS increases the secretion of
proinflammatory cytokines from synovial fibroblasts
Cultures of RASFs and OASFs were stimulated with
HMGB1, LPS or complexes of HMGB1 and LPS, and the
resultant cytokine production was analysed using Elispot
and CBA. Stimulation with 4 μg/ml HMGB1 did not
induce TNF production in cultures of RASFs or OASFs.
The selected doses, 1 to 100 ng/ml of LPS did not induce
any or only minor TNF production above background
levels. In contrast, significant TNF production occurred
when RASF or OASF were stimulated with HMGB1 prein-
cubated with 1 to 100 ng/ml LPS as compared to HMGB1
or LPS alone (Figure 2a). To define whether the enhance-
ment of TNF production was an isolated effect or if
HMGB1-LPS complex stimulation affected the production
of additional cytokines we also analyzed the production of
IL-10, IL-1b, IL-6 and IL-8 using CBA. Similarly to the
induced TNF production, HMGB1 in complex with LPS
synergistically increased IL-6 and IL-8 production from
both RASF and OASFs in a dose-dependent manner (Fig-
ure 2b). The synergistic effects of the complexes were sta-
tistically significant with a 5 to 15 and 10- to 20-fold
increase in IL-6 and IL-8 production, respectively, as com-
pared to 100 ng/ml LPS stimulation alone. Confirming the
previously reported necessity of a preformed complex for-
mation between HMGB1 and LPS, simultaneous addition
of HMGB1 and LPS to cell cultures did not result in
enhanced cytokine production (data not shown).
No induction of IL-10 or IL-1b production could be
detected after 24 h of stimulation with HMGB1 alone,
LPS alone or HMGB1 in complex with LPS. As the cyto-
kine response detected by Elispot or CBA did not differ
significantly between RASFs and OASFs, median values
of recorded data from these experiments are indicated
with horizontal line in Figure 2a, b.
Thus, similarly to results previously demonstrated
using human peripheral blood mononuclear cells
(PBMCs) [18], RASFs and OASFs respond to HMGB1
in complex with LPS by an enhanced cytokine produc-
tion. OK
HMGB1 in complex with IL-1b increases proinflammatory
cytokine secretion from synovial fibroblasts
Previous reports indicate that HMGB1 can interact with
IL-1b through formation of complexes with enhanced sti-
mulatory capacity [17,18], which is of interest regarding
arthritis pathogenesis as both IL-1a and IL-1b are abun-
dant proinflammatory cytokines in the RA arthritic joint
and they have also been detected in OA joints [38,39].
RASFs and OASFs responded to IL-1b stimulation alone
using a high IL-1b dose of 0.5 ng/ml. In contrast, when
using a physiologically more relevant IL-1b dose of
0.05 ng/ml synovial fibroblasts did not produce cytokines.
In accordance with the enhancing effects of HMGB1 in
complex with LPS, preformed complexes of HMGB1 and
the suboptimal dose of IL-1b induced a significant pro-
duction of TNF (Figure 3a), and also of IL-6 and IL-8
(Figure 3b). The IL-6 production was increased 30- to
180-fold and IL-8 production by 100- to > 400-fold when
stimulated with HMGB1-IL-1b complexes compared to
stimulation with the suboptimal IL-1b concentration
alone. No effect on the production of IL-10 or IL-1b
could be detected when complexes were applied. Com-
pared to the HMGB1-LPS complex experiments, the
dose of HMGB1 used was much lower, 100 ng/ml, in this
experimental setting, demonstrating that low, cytokine-
like levels of HMGB1 display a potentiating effect on
cytokine production. As the cytokine response detected
by Elispot or CBA did not differ significantly between
RASFs and OASFs, median values of pooled recorded
data from these experiments are indicated with horizon-
tal line in Figure 2a, b.
HMGB1-IL-1b complex stimulation induced higher
cytokine levels than HMGB1-LPS complex stimulation
and, correspondingly, high dose IL-1b alone was more
potent in inducing cytokine production than was high
dose LPS alone (Figures 2a, b and 3a, b). Furthermore,
simultaneous addition of both HMGB1 and the subopti-
mal dose of IL-1b (without complex formation) to cell cul-
tures did not raise cytokine production above background
levels (data not shown), underlining the importance of
complex formation between HMGB1 and IL-1b.
Enhanced MMP-3 production following stimulation with
complexes of HMGB1 and IL-1b
Destructive features of arthritis are partly due to the
production of MMPs with the ability to degrade extra-
cellular matrix and cartilage. We investigated whether
production of MMP-3, a cartilage-degrading MMP,
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with HMGB1-IL-1b complexes.
Both RASFs and OASFs spontaneously released MMP-
3. Despite the differences in spontaneous MMP-3 pro-
duction all but one cell line responded with significantly
enhanced MMP-3 production following stimulation with
HMGB1 in complex with IL-1b (Figure 3c). Enhanced
MMP-3 production was observed in the non-responding
cell line when stimulated with HMGB1 in complex with
a higher dose of IL-1b (0.5 ng/ml), data not included in
Figure 3c. This could suggest that the enhancing poten-
tial of HMGB1 in complex with IL-1b is dependent on
the response to IL-1b as the ligand.
HMGB1-LPS complexes utilise TLR4 signalling for
induction of cytokine production
In order to elucidate the receptor dependence of the
cytokine-enhancing effects of the investigated HMGB1-
ligand complexes we investigated TLR4 requirement for
HMGB1-LPS mediated cytokine production. RASFs and
Figure 1 TLR4 and IL-1RI are expressed on synovial fibroblasts. Synovial fibroblasts were cultured in chamber slides without exogenous
stimulation. TLR4 and IL-1RI expression was determined by immunocytochemical staining (red Alexa Fluor
© 594) and nuclei were counterstained
with Hoechst (blue). A) TLR4 staining, B) IL-1RI staining, C) staining with TLR4 specific antibody pre-incubated with blocking peptide, D) control
staining with irrelevant rabbit IgG.
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the fatty acid moieties of the lipid A portion removed,
resulting in a TLR4-binding LPS with 10,000-fold lower
toxicity than regular LPS) for 1 to 2 h followed by sti-
mulation with HMGB1 in complex with LPS.
Detoxified LPS inhibited HMGB1-LPS complex-
mediated IL-6 and IL-8 production from RASFs and
OASFs (Figure 4), thus demonstrating a TLR4 dependency
for the cytokine-inducing signalling events induced by
HMGB1 in complex with LPS. Similarly, pre-incubation
with detoxified LPS inhibited the low cytokine production
induced by stimulation with LPS alone (Figure 4).
HMGB1-IL-1a and HMGB1-IL-1b complexes utilise IL-1RI
signalling for induction of cytokine production
Similar to complexes of HMGB1-IL-1b, complexes of
HMGB1 with IL-1a stimulated RASFs and OASFs to sig-
nificantly increased production of IL-8 and IL-6 deter-
mined by CBA, as compared to IL-1a alone (Figure 5a).
In order to investigate the role of the signalling IL-1
receptor, IL-1RI, for the observed cytokine production
induced by HMGB1 in complex with IL-1a or IL-1b we
utilised IL-1RA, Anakinra. RASFs and OASFs were incu-
bated with IL-1RA for 1 h prior to stimulation with
HMGB1, IL-1a,I L - 1 b and HMGB1 in complex with
either IL-1a or IL-1b. IL-1RA significantly inhibited
HMGB1-IL-1a complex mediated IL-6 and IL-8 produc-
tion from RASFs and OASFs (Figure 5a) and HMGB1-IL-
1b complex-mediated TNF (Figure 5b), IL-6 and IL-8
(Figure 5c) production from RASFs and OASFs. Our
results indicate that IL-1RI serves as a signalling receptor
for HMGB1-IL-1a- and HMGB1-IL-1b complex-mediated
cytokine production.
HMGB1-IL-1b-complexes do not utilise TLR4 signalling for
induction of cytokine production
HMGB1 has been demonstrated to interact with TLR4
and thereby to induce cytokine production [13,46].
Although the HMGB1 used in this study did not express
any cytokine-inducing ability per se, we wanted to ascer-
tain that the enhancing effects of the HMGB1-IL-1b
complex were not due to an interaction of HMGB1 with
TLR4. RASFs and OASFs were incubated with detoxified
LPS 1 to 2 h prior to stimulation with HMGB1 alone or
HMGB1-IL-1b-complexes and cytokine production was
recorded. No significant reduction of the HMGB1-IL-1b
complex-induced IL-6 and IL-8 production could be
recorded as a consequence of pre-treatment with detoxi-
fied LPS (Figure 6). Our results thus demonstrate that
the cytokine-enhancing ability of HMGB1-IL-1b com-
plexes is dependent on IL-1RI signalling but not on
TLR4 signalling.
Discussion
Herein we reveal a mechanism by which HMGB1 may
contribute to both inflammatory and destructive pro-
cesses present during arthritis. Synovial fibroblasts stimu-
lated with HMGB1 in complex with IL-1a,I L - 1 b or LPS
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for nine hours with A) HMGB1, LPS or HMGB-LPS with the indicated concentrations. The addition of HMGB1-LPS complex to cells induced a 1
to 2 log-fold increased number of TNF producing cells recorded by Elispot. Individual results from RA (squares) and OA (dots) represent results
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HMGB1-IL-1b complexes also increased MMP-3 pro-
duction. Previous studies have demonstrated that
HMGB1 is released from activated immune cells and
from stressed synoviocytes in arthritic joints and that
blockade of extracellular HMGB1 suppresses disease pro-
gression in experimental models. Here we demonstrate
that HMGB1 potentiates the effects of two endogenous
molecules reported to be present in arthritic joints,
namely IL-1a/IL-1b and the microbial mediator LPS.
The enhancing effects are caused by complex formation
between HMGB1 and the partner molecules. Such
immunostimulatory features of HMGB1 in complex with
IL-1b and LPS have previously been reported by us and
others, while the synergistic effects of HMGB1 and IL-1a
are described for the first time in this study.
So, in addition to the direct cytokine-inducing effects of
HMGB1 previously reported, our results suggest that the
arthritogenic features of HMGB1 can also be mediated
by the enhanced activity of molecules in complex with
HMGB1. HMGB1 that is actively secreted by activated
macrophages or passively released from necrotic cells sig-
nals via TLR4 since the TLR4-binding epitope of the
HMGB1 molecule expresses its cysteine in position 106
(C106) in reduced form, which is a prerequisite for acti-
vation of this signal pathway [47,13]. The C106 may then
later be oxidized in the inflammatory milieu and will lose
its capacity to signal via the TLR4 complex. However,
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Figure 3 HMGB1 in complex with IL-1b stimulates SFs to TNF, IL6, IL-8 and MMP-3 production. Synovial fibroblasts were stimulated for
nine hours with A) HMGB1, IL-1b or HMGB1-IL-1b complexes. Addition of HMGB1-IL-1b complexes stimulates RASFs and OASFs to a 1 to 2 log-
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production, stimulation with HMGB1-IL-1b complex enhanced the production in 8/9 cell lines compared to HMGB1 simulation alone. Squares
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Page 7 of 12this pacified version of HMGB1 may still act as a proin-
flammatory molecule if the environment contains danger
molecules like IL-1a, IL-1b or LPS. HMGB1 will then act
as an extracellular sensor and form complexes with these
molecules that will enhance subsequent cytokine produc-
tion in fibroblasts and other cells.
The ligands for complex formation with HMGB1 in
this study, IL-1a,I L - 1 b and LPS, were chosen for three
reasons; I) we and others have previously demonstrated a
cytokine-enhancing effect of such complexes in macro-
phages [16,17,48]; II) HMGB1 [23], LPS [42], IL-1a and
IL-1b [38-40] have all been detected in RA and OA syno-
vial samples; and III) fibroblasts are pivotal cells in
arthritic inflammation that express the suggested recep-
tors for HMGB1 [23,35,49-51] in addition to the LPS
receptor TLR4 and IL-1RI [34-37].
Complexes of HMGB1 with IL-1a,I L - 1 b or LPS each
strongly enhanced the production of TNF, IL-6 and IL-8,
while the production of both IL-10 and IL-1b was not
affected. It is of interest to note that fibroblasts retrieved
from both OA and RA patients shared a similar ability to
respond to HMGB1-complex stimulation. Previous stu-
dies have reported a difference in extracellular HMGB1
levels in RA and OA synovial fluid with HMGB1 levels
being significantly higher (54.1 ± SD 73.0 ng/ml) in RA
synovial fluid than in OA synovial fluid (12.0 ± SD 17.7
ng/ml [23]. Similarly, the IL-1b levels recorded in syno-
vial fluid levels from RA patients are roughly 10 times
higher than those recorded in OA patients [39]. One can
thus assume that HMGB1-IL-1b complexes are more
likely formed in vivo during RA than during OA. This
could affect the activation status of synovial fibroblasts
contributing to a more inflammatory and destructive dis-
ease course in RA than in OA.
The amounts of HMGB1 and IL-1b used in our study
correspond to levels recorded in RA synovial fluid;
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Figure 4 HMGB1 in complex with LPS utilizes TLR4 for the induction of cytokine production. Synovial fibroblasts were pretreated with
detoxified LPS for one to two hours prior to the indicated stimulations. After 24 hours of stimulation, production of IL-8 and IL-6 were
determined by CBA. Detoxified LPS blocked the induction of IL-8 and IL-6 production from HMGB1-LPS complex- stimulated synovial fibroblasts.
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Whitney test. * (P < 0.05) ** (P < 0.01) *** (P < 0.001).
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Page 8 of 12ranging from 10 to 300 ng/ml and 5 to 193 pg/ml,
respectively [23,40,52]. A study by Garcia-Arnandis
et al. [25] demonstrated that simultaneous addition of
HMGB1 and IL-1b induced enhanced IL-6 and IL-8
production in OA synovial fibroblast cultures, which we
did not observe in our study. However, the IL-1b con-
centration used in their experiments was 20-fold higher
than in our experimental setup, and also higher than
levels recorded in RA synovial fluid. It is plausible that
the high IL-1b levels used could lead to HMGB1-IL-1b
complex formation during the cell stimulation and thus
their findings are in agreement with our results.
LPS, as well as other constituents of various pathogens,
have been reported to be present in arthritic joints
[41,42]. This has led to the hypothesis that infections can
be both a cause of arthritis onset and also of disease
exacerbation. However, no infectious agent in particular
has been pinpointed to be associated with chronic arthri-
tis. The data presented in this paper together with earlier
studies on the interaction of HMGB1 with different TLR-
ligands suggest that HMGB1 might be a unifying factor
for the contribution of various infections to arthritis
pathogenesis.
Our data clearly demonstrate the striking ability of
HMGB1 complexes to enhance both cytokine production
and MMP-3 production by SFs when compared to
equivalent doses of the ligand molecules alone. We had
originally hypothesized that the enhancing effects would
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Figure 5 HMGB1 in complex with IL-1a or IL-1b utilizes IL-1RI for the induction of cytokine production. Synovial fibroblasts were pre-
incubated with soluble IL-1RA one to two hours prior to indicated stimulation. IL-1RA significantly inhibited the: A) HMGB1-IL-1a complex
mediated IL-8 and IL-6 production compared with untreated groups, determined by CBA (pooled data from RASFs and OASFs n = 6), B) HMGB1-
IL-1b mediated TNF production, compared with untreated group, determined with Elispot (pooled data from RASFs and OASFs n = 4) and C)
HMGB1-IL-1b complex-mediated IL-8 and IL-6 production compared with untreated groups, determined by CBA (pooled data from RASFs and
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Page 9 of 12be mediated by simultaneous engagement of an HMGB1
receptor (RAGE or TLR4) and the partner ligand recep-
tor. By blocking IL-1RI and TLR4 with the respective
receptor antagonists (IL-1 receptor antagonist or detoxi-
fied LPS) we could demonstrate that the stimulatory
activities of the HMGB1-IL-1a and IL-1b complexes
were mediated via the IL-1RI and that the stimulatory
activity of the HMGB1-LPS complex was mediated via
TLR4. Interestingly, blockade of TLR4 did not suppress
the stimulation induced by HMGB1-IL-1b complexes,
thus ruling out that the synergistic effects were mediated
by a simultaneous interaction of TLR4 and IL-1RI. This
conclusion is also supported by the fact that the HMGB1
used in our studies did not alone possess an endogenous
cytokine-inducing capacity, this otherwise being
mediated through TLR4 interaction [13,46]. Attempts to
block RAGE, the most studied receptor for HMGB1,
using a receptor antagonist failed as we could not define
a functional antagonist. Results from studies when solu-
ble RAGE (sRAGE) was added to the cell culture (data
not included) demonstrated that sRAGE could suppress
the activity of the HMGB1 complexes. However, this
only confirms that HMGB1 can bind to RAGE; the
suppressive effects were most likely caused by steric hin-
drance rather than by an inactivation of RAGE signalling.
Data from our laboratory (H. Hreggvidsdottir et al., sub-
mitted manuscript) indicate that RAGE is not involved in
HMGB1 complex signaling as macrophages from RAGE-
deficient mice respond equally well to HMGB1 complex
stimulation as from wild type mice. However, a remain-
ing possibility for the mechanism of HMGB1 complex-
induced enhancement could be the involvement of an as
yet undefined HMGB1 receptor in a receptor-pair with
the partner ligand receptor. A second possibility could be
a multiaggregation of ligand receptors caused by the
HMGB1-ligand complex leading to enhanced activity.
Both scenarios deserve further investigations.
Conclusions
Preformed complexes of HMGB1 with IL-1a,I L - 1 b or
LPS have the ability to strongly enhance production of
both proinflammatory mediators and of tissue destructive
enzyme by synovial fibroblasts derived from RA and OA
patients. HMGB1 thus acts as an endogenous amplifier
endowed with a capacity to magnify responses to trace
amounts of endogenous and exogenous danger signals.
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Figure 6 HMGB1-IL-1b complexes do not utilise TLR4 signalling for induction of cytokine production. Synovial fibroblasts were incubated
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complex-mediated cytokine production (pooled data SF n = 4). Data were analysed using Mann Whitney test.
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IL-1RI and TLR4, for the ligands complexed to HMGB1
investigated in this study. HMGB1 without direct cyto-
kine-inducing effects on its own might be present in
arthritic joints as HMGB1 is released by apoptotic cells.
Furthermore, exposure of cytokine-inducing, reduced
HMGB1 to an oxidative burst during inflammation may
downregulate its direct proinflammatory features by
changing its redox status. We demonstrate that non-
cytokine-inducing HMGB1 can form strongly inflamma-
tion-enhancing complexes with inflammatory mediators
present in arthritic joints. These HMGB1 complexes act
on both synovial fibroblasts and on monocytes and
enhance their activation status. Thus in addition to the
direct cytokine-inducing effect of HMGB1 previously
described, we, herein, demonstrate a second mechanism
by which HMGB1 may contribute to the arthritogenic
process.
Through this study we have increased knowledge of
the proinflammatory functions of HMGB1 in arthritis in
both RA and OA settings. We have demonstrated
enhancing effects of HMGB1 on both inflammatory and
destructive disease mechanisms and further consolidated
HMGB1 as a putative target for successful therapy.
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